Want to join the conversation?
$ICPT plans to lift its research and development expenses for foreseeable future as it continue development of obeticholic acid, or OCA, for treatment of primary biliary cirrhosis (PBC), NASH and primary sclerosing cholangitis (PSC) and other indications and to further advance development of other product candidates.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.